10X average volume run on study enrollment, two analysts calls for $6-7$ Price targets, but rally fading on high volume,, discouraging. High short interest too, but can't see significant downside absent a negative clinical data release so you think there would be more covering since it's down 85% from its 52 week high! I have a feeling the market isn't attracting any buyers here until they show some promising data for the compounds in development? Anyone have any ideas when that will be?
This is not hype, legit deal with major partner - Up to 297 Million over five years, and no debt, seems like it's flying under the radar, should go higher in near term, but when earnings are announced it will definitely jump. The balance sheet doesn't lie!
None of these reporting services are reliable. They reported they had a 3q eps of .32 vs .85 expectations, the latter figure is for 4Q. FYI
Considering MTX has been standard of care but limited because of its bioavailability with current delivery system, this could be a required step before moving to Enbrel, Humira and other significantly more expensive biologics
saw a sell off after Fortune's article, Yelp sold off from 69.40 to 68.45 while Nasdaq climbed. IMO concerns over fake review issue may be getting mainstream coverage raising credibility concerns over the model. Also concerns over listed businesses bringing litigation for business impact of damaging reviews or inflated reviews of competitors, which would be made possible if Yelp is found guilty and fined.
This is not an apples to apples comparison, any drug will perform better with a Metformin boost, when compared to a single oral comparison drug - if you gave that patients in the comparitor arm metformin they would be equivallent. Reading way too much into this data.
Previous poster lied, he did not say STRONG BUY, he likes the company and products but would not based on it's price/valuation which he thinks is far ahead of it's growth
this post has been reported to yahoo, this post and others will be sent as evidence to the governing body of online content who make assessments for possible criminal prosecution. Use of explicit language and the threat of sexual abuse, is taken seriously regardless of the posters intent. This is a business/finance message board intended as a forum to express views on this particular stock or the market in general. It is not a outlet for fringe characters to vent their rage because they are not brave enough to stand up to anyone in the real world. Perhaps you should climb out of your parents basement once in a while, shed your pajamas and perhaps seek the help of a professional. In the mean time, expect to hear from someone from yahoo or the FCC. I'm not kidding.
I feel your pain - I actually bought today! Even having read the Barron's article there seemed to be little impact on the stock, there weren't any downgrades or price target changes in reaction to the article, so I don't buy that this was a response to Barron's from nervous investors, that knee jerk stuff happens immediately - the volume was too scary, almost the whole float. Maybe this is typical wall street slime manipulating stock, or maybe there is bad news, but what ticks me off is the lousy investor relations here. This was the number one decliner today, hurrendous volume and not one word from someone from the company to calm investors. Usually they at least issue a statement, acknowledging the price move of the stock and that they know of no reason for it. If there is news that comes out on Monday that's bad than a shareholder lawsuit is likely and should have the SEC investigate
hard balls of steel, brains of cotton, how old are you anyway? Have a little dignity if you're even capable.
if you haven't jumped off the ledge yet how about a shout out to the shareholders? Or are you waiting until Monday when we're trading on the pink sheets?
I hope you're right! I bought today at the open!!!!! lucky me to go bust on an upmarket day. I agree though, this is about innovation, there's bound to be skeptics, should be an upside correction when the dust settles
who knows if there really was a conference call, it just said there was on that Benziger service, seems mysterious to have a five day delay in a reaction to the Barrons article, it could just be some large fund who got in at 9 bucks and cashing out. My guess is if there's news it will be released after the extended hours trading and if its bad you know there was insider trading going on. The shareholder suits are usually handled on contingency basis if it comes to that. I just got in today, lucky me to lose big on an up market day :(
Why do people keep talking about short covering? This stock is at new highs and just lost near term revenue, yes they have a pipeline, but nothing that should drive the stock price much higher than the 18-19 price target - I have no idea what drove the spike today, there were a couple of "maintain ratings" from analysts but not much validation of why
Good point. Dumb question, or maybe naive but wouldn't a move against china (unfair trade practice) be good for ole Molly??
I'm with ya, and I'm long the stock, but don't jinx it by saying the approval is "in the bag" that author was totally irresponsible saying that, FDA and IN THE BAG should never be in the same sentence, ask anyone who works at a pharma company like me. I'm concerned the run up today was an over reaction to his very self serving comments. That information he discussed is not new, and the rapid run up meant that nobody bothered to validate his comments, you couldn't possible disseminate a clinical trial that quickly, but people just piled in. IT's scary. Same thing happened to GNOM, up 40% in one day then totally erased it two days later and went further south. Different circumstances, but similar in that the information they released was not fully baked